PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Pfizer
Pfizer to Acquire King Pharmaceuticals
The merger, announced on Tuesday, will cost Pfizer $3.6 billion.
Pfizer and King Pharmaceuticals announced on Tuesday they have entered into a definitive friendly merger agreement. Under the terms, Pfizer will acquire King, a diversified specialty pharmaceutical company based in Tennessee, for $3.6 billion in cash, or $14.25 per share. The company emphasized the deal is not [...]
Pfizer Ends Sutent Trial
Successful cancer drug Sutent may not be effective in prolonging life for patients with castration-resistant prostate cancer.
This week, Pfizer announced that it has ended a Phase III trial of cancer drug Sutent. The drug, which was being tested as a treatment for patients with prostate cancer, has already been approved as a treatment for kidney [...]
Pfizer and American Kennel Club Team Up For New Research
Pfizer’s Animal Health unit has signed an exclusive deal with the American Kennel Club’s Canine Health Foundation (CHF)—the largest nonprofit worldwide—to fund health research exclusively for canines.
This new research partnership names Pfizer Animal Health the sole biopharmaceutical partner of CHF, and begins with Pfizer committing to provide an initial $50,000 over a two-year period.
According to [...]
Pfizer Adds FoldRx to its Specialty Care Unit
Pfizer on Wednesday announced that it acquired a small rare-disease drug firm, FoldRx, for an undisclosed sum of money.
Pfizer spokeswoman Gwen Fischer told Pharm Exec that the deal came together in a matter of weeks, and that FoldRx will be fully incorporated into Pfizer’s research division. All of FoldRx’s employees are expected to become Pfizer [...]
The High Cost of Staying Lean